Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form (ICF)~* Male or non-pregnant, non-lactating female participants, 18 to 50 years of age (inclusive) as of signing the ICF~* Diagnosis of MS per McDonald's update of the Poser criteria, including cranial MRI consistent with those criteria (McDonald, 2001, Ann Neurol)~* Onset of first MS symptoms within 3 years prior to Screening as of signing the ICF~* Expanded Disability Status Scale (EDSS) score 0.0 to 3.0 (inclusive) at the screening and Baseline visits~* At least 2 completed clinical episodes of MS in the 2 years prior to study entry (that is, the initial event if within 2 years of study entry plus at least 1 relapse, or at least 2 relapses if the initial event was between 2 and 3 years prior to study entry)~* In addition to the clinical criteria, at least 1 enhancing lesion on any 1 of up to 4 screening gadolinium-enhanced MRI brain scans during a maximum 3-month run-in period (inclusive of the Month 0 Baseline scan)~Exclusion Criteria:~* Previous immunotherapy for MS other than steroids, including treatment with interferons, intravenous immunoglobulin (IVIG), glatiramer acetate, and mitoxantrone~* Personal history of thyroid autoimmune disease~* Personal history of clinically significant autoimmune disease (for example, inflammatory bowel disease, diabetes, lupus, severe asthma)~* History of thyroid carcinoma (previous thyroid adenoma was acceptable and was not considered an exclusion criterion)~* History of malignancy (except for basal cell skin carcinoma if disease-free for at least 5 years)~* Any disability acquired from trauma or another illness that, in the opinion of the Investigator, interfered with evaluation of disability due to MS~* Previous treatment with alemtuzumab~* History of anaphylaxis following exposure to humanized monoclonal antibodies~* Inability to undergo MRI with gadolinium administration~* Female participants of childbearing potential with a positive serum pregnancy test at screening or Baseline~* Male and female participants who did not agree to use effective contraceptive method(s) during the study~* Impaired renal function (that is, serum creatinine greater than or equal to 2 times the upper limit of normal \[ULN\])~* Untreated, major depressive disorder~* Epileptic seizures that were not adequately controlled by treatment~* Suicidal ideation~* Major systemic disease or other illness that, in the opinion of the Investigator, have compromised participant safety or interfered with the interpretation of study results~* Abnormal CD4 count or significantly abnormal thyroid function; presence of anti-thyroid stimulating hormone (TSH) receptor antibodies; known seropositivity for human immunodeficiency (HIV)~* Intolerance of pulsed corticosteroids, especially a history of steroid psychosis~* Presence of a monoclonal paraprotein~* Participants who had any form of MS other than relapsing-remitting~* Participants currently participating in a clinical study of an experimental or unapproved/unlicensed therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Interferon Beta-1a (Type: ACTIVE_COMPARATOR): None
- Alemtuzumab 12 mg (Type: EXPERIMENTAL): None
- Alemtuzumab 24 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete